デフォルト表紙
市場調査レポート
商品コード
1492454

線維嚢胞性乳房の診断・治療の市場規模 - タイプ・エンドユーザー別 - 地域別展望・競合戦略・セグメント予測 (~2033年)

Fibrocystic Breasts Diagnostics Treatment Market Size- By Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

出版日: | 発行: SPER Market Research Pvt. Ltd. | ページ情報: 英文 211 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
線維嚢胞性乳房の診断・治療の市場規模 - タイプ・エンドユーザー別 - 地域別展望・競合戦略・セグメント予測 (~2033年)
出版日: 2024年06月03日
発行: SPER Market Research Pvt. Ltd.
ページ情報: 英文 211 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の線維嚢胞性乳房の診断・治療の市場規模は、2033年にかけて8.11%のCAGRで推移し、311億7,000万米ドルの規模に成長すると予測されています。

世界の線維嚢胞性乳房の診断・治療の市場は、COVID-19の流行によって大きな影響を受けています。COVID-19患者を優先し、感染のリスクを下げるため、流行のピーク時には緊急性のない治療の多くが中止または延期されました。その結果、線維嚢胞性乳房疾患の患者は診断や治療経過が遅れ、合併症を引き起こしたり、病気が進行したりした可能性があります。

当レポートでは、世界の線維嚢胞性乳房の診断・治療の市場を調査し、市場概要、市場影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 促進要因・抑制要因・機会・課題の分析
  • COVID-19の市場への影響

第5章 市場変数と見通し

  • SWOT分析
  • PESTEL分析
  • ポーターのファイブフォース分析
  • ヒートマップ分析

第6章 競合情勢

  • 製造拠点の分布・販売エリア・製品タイプ
  • M&A・提携・製品発売・協力

第7章 世界の線維嚢胞性乳房の診断・治療市場:タイプ別

  • 世界市場の規模・シェア・予測
  • 診断
  • マンモグラフィー
  • 乳房生検
  • 治療
  • 医薬品
  • アセトアミノフェン
  • 非ステロイド性抗炎症薬
  • 穿刺吸引法
  • 外科的切除
  • 経口避妊薬

第8章 世界の線維嚢胞性乳房の診断・治療市場:エンドユーザー別

  • 世界市場の規模・シェア・予測
  • 病院
  • クリニック
  • 診断センター
  • 専門クリニック・リハビリセンター
  • 研究機関
  • その他

第9章 世界の線維嚢胞性乳房の診断・治療市場の予測

  • 市場規模・市場シェア

第10章 世界の線維嚢胞性乳房の診断・治療市場:地域別

  • 市場規模・市場シェアの推移・予測
  • アジア太平洋
  • 欧州
  • 中東・アフリカ
  • 北米
  • ラテンアメリカ

第11章 企業プロファイル

  • Argon Medical Devices
  • Becton, Dickinson and Company
  • Bayer AG
  • Boston Scientific Corp.
  • Devicor Medical Products Inc.
  • Johnson & Johnson Pvt. Ltd.
  • Merck
  • Sanofi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries Ltd.
  • その他

第12章 結論

第13章 略語一覧

第14章 参考リンク

目次
Product Code: HLCA2458

Fibrocystic Breasts Diagnostics Treatment Market Introduction and Overview

According to SPER market research, 'Fibrocystic Breasts Diagnostics Treatment Market Size- By Types, By End-Users - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Fibrocystic Breasts Diagnostics Treatment Market is predicted to reach USD 31.17 billion by 2033 with a CAGR of 8.11%.

Breasts feeling lumpy are a symptom of fibrocystic breast disease, a non-cancerous illness also called fibrocystic change or fibrocystic breasts. The breast lumps are caused by fibrocystic changes. These lumps develop from a concentration of fibrous tissue in one area of the breast. Changes in breast tissue brought on by fluctuations in hormone levels produced by the ovaries are the cause of fibrocystic breasts.

The worldwide market for fibrocystic breast diagnosis and therapy has been greatly influenced by the COVID-19 epidemic. Many non-urgent medical treatments were canceled or postponed during the peak of the pandemic in order to prioritize COVID-19 patients and lower the risk of transmission. As a result, people who have fibrocystic breast disorders might have had delays in their diagnosis and course of treatment, which could have resulted in complications or the advancement of their illness.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Types, By End Users

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Argon Medical Devices, Becton,Dickson and Company, Bayer AG, Boston Scientific Corp, Devicor Medical Products Inc., Johnson & Johnson Pvt. Ltd., Merck, Sanofi, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd.

Global Fibrocystic Breasts Diagnostics Treatment Market Segmentation:

By Types: Based on the Types, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Diagnosis, Mammogram, Breast Biopsy, Treatment, Medications, Acetaminophen. Non-steroidal anti-inflammatory Drugs, Fine-Needle Aspiration, Surgical Excision, Oral Contraceptive

By End-Users: Based on the End-Users, Global Fibrocystic Breasts Diagnostics Treatment Market is segmented as; Hospitals, Clinics, Diagnostic Centers, Speciality Clinics and Rehab Centers, Research Institutes, Others.)

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Fibrocystic Breasts Diagnostics Treatment Market.

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Fibrocystic Breasts Diagnostics Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Fibrocystic Breasts Diagnostics Treatment Market

7. Global Fibrocystic Breasts Diagnostics Treatment Market, By Type (USD Million) 2020-2033

  • 7.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2020-2026
  • 7.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By Type, 2027-2033
  • 7.3. Diagnosis
  • 7.4. Mammogram
  • 7.5. Breast Biopsy
  • 7.6. Treatment
  • 7.7. Medications
  • 7.8. Acetaminophen
  • 7.9. Non-steroidal Inflammatory Drugs
  • 7.10. Fine-needle Aspirations
  • 7.11. Surgical Excision
  • 7.12. Oral Contraceptives

8. Global Fibrocystic Breasts Diagnostics Treatment Market, By End-Users (USD Million)2020-2033

  • 8.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2020-2026
  • 8.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size Share and Forecast, By End Users, 2027-2033
  • 8.3. Hospitals
  • 8.4. Clinics
  • 8.5. Diagnostic Centers
  • 8.6. Speciality Clinics and Rehab Centers
  • 8.7. Research Institutes
  • 8.8. Others

9. Global Fibrocystic Breasts Diagnostics Treatment Market Forecast, 2020-2033 (USD Million)

  • 9.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share

10. Global Fibrocystic Breasts Diagnostics Treatment Market, By Region, 2020-2033 (USD Million)

  • 10.1. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2020-2026)
  • 10.2. Global Fibrocystic Breasts Diagnostics Treatment Market Size and Market Share By Region (2027-2033)
  • 10.3. Asia-Pacific
    • 10.3.1. Australia
    • 10.3.2. China
    • 10.3.3. India
    • 10.3.4. Japan
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. Europe
    • 10.4.1. France
    • 10.4.2. Germany
    • 10.4.3. Italy
    • 10.4.4. Spain
    • 10.4.5. United Kingdom
    • 10.4.6. Rest of Europe
  • 10.5. Middle East and Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Qatar
    • 10.5.4. South Africa
    • 10.5.5. Egypt
    • 10.5.6. Morocco
    • 10.5.7. Nigeria
    • 10.5.8. Rest of Middle East & Africa
  • 10.6. North America
    • 10.6.1. Canada
    • 10.6.2. Mexico
    • 10.6.3. United States
  • 10.7. Latin America
    • 10.7.1. Argentina
    • 10.7.2. Brazil
    • 10.7.3. Rest of Latin America

11. Company Profile

  • 11.1. Argon Medical Devices
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Becton, Dickinson and Company
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Bayer AG
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. Boston Scientific Corp.
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Devicor Medical Products Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Johnson & Johnson Pvt. Ltd.
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Merck
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Sanofi
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. Sun Pharmaceutical Industries
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. Teva Pharmaceutical Industries Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. Others

12. Conclusion

13. List of Abbreviations

14. Reference Links